Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective
https://doi.org/10.4081/dr.2023.9839
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
This comprehensive review offers a detailed look at atopic dermatitis (AD) treatment in Italy, focusing primarily on the use of biologics and small molecules. In response to advancing knowledge of AD's causes and treatments, there's a global need for updated guidelines to provide physicians with a more comprehensive clinical perspective, facilitating personalized treatment strategies. Dupilumab, a groundbreaking biologic, gained approval as a significant milestone. Clinical trials demonstrated its ability to significantly reduce AD severity scores, with an impressive 37% of patients achieving clear or nearly clear skin within just 16 weeks of treatment. Real-world studies further support its efficacy across various age groups, including the elderly, with a safety profile akin to that of younger adults. Tralokinumab, a more recent approval, shows promise in clinical trials, particularly among younger populations. However, its real-world application, especially in older individuals, lacks comprehensive data. JAK inhibitors like Upadacitinib, baricitinib, and abrocitinib hold substantial potential for AD treatment. Nevertheless, data remains limited for patients over 75, with older adults perceived to carry a higher risk profile. Integrated safety analyses revealed individuals aged 60 and above experiencing major adverse cardiovascular events and malignancies, underscoring the need for cautious consideration. While these therapies offer promise, especially among younger patients, further research is essential to determine their safety and efficacy in various populations, including pediatric, geriatric, and those with comorbidities. This review highlights the evolving landscape of AD treatment, with biologics and small molecules emerging as potent tools to enhance the quality of life for AD-affected individuals.
Paller A, Jaworski JC, Simpson EL, Boguniewicz M, Russell JJ, Block JK, et al. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. Am J Clin Dermatol. 2018 Dec;19(6):821–38. DOI: https://doi.org/10.1007/s40257-018-0383-4
Eichenfield LF, Hanifin JM, Beck LA, Lemanske RF, Sampson HA, Weiss ST, et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics. 2003 Mar;111(3):608–16. DOI: https://doi.org/10.1542/peds.111.3.608
Ali FR. Does this patient have atopic asthma? Clin Med Lond Engl. 2011 Aug;11(4):376–80. DOI: https://doi.org/10.7861/clinmedicine.11-4-376
Weinmayr G, Weiland SK, Björkstén B, Brunekreef B, Büchele G, Cookson WOC, et al. Atopic Sensitization and the International Variation of Asthma Symptom Prevalence in Children. Am J Respir Crit Care Med. 2007 Sep 15;176(6):565–74. DOI: https://doi.org/10.1164/rccm.200607-994OC
Pyun BY. Natural History and Risk Factors of Atopic Dermatitis in Children. Allergy Asthma Immunol Res. 2015 Mar;7(2):101–5. DOI: https://doi.org/10.4168/aair.2015.7.2.101
Saco T, Ugalde IC, Cardet JC, Casale TB. Strategies for choosing a biologic for your patient with allergy or asthma. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2021 Dec;127(6):627–37. DOI: https://doi.org/10.1016/j.anai.2021.09.009
van de Veen W, Akdis M. The use of biologics for immune modulation in allergic disease. J Clin Invest. 129(4):1452–62. DOI: https://doi.org/10.1172/JCI124607
Panettieri RA, Sjöbring U, Péterffy A, Wessman P, Bowen K, Piper E, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018 Jul;6(7):511–25. DOI: https://doi.org/10.1016/S2213-2600(18)30184-X
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018 Jun 28;378(26):2486–96. DOI: https://doi.org/10.1056/NEJMoa1804092
Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018 Jun 28;378(26):2475–85. DOI: https://doi.org/10.1056/NEJMoa1804093
Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol JEADV. 2023 Jun;37(6):1135–48. DOI: https://doi.org/10.1111/jdv.18922
Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Thaçi D, Blauvelt A, et al. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1212-1223.e6. DOI: https://doi.org/10.1016/j.jaip.2020.12.059
Braithwaite IE, Cai F, Tom JA, Galanter JM, Owen RP, Zhu R, et al. Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial. J Allergy Clin Immunol. 2021 Sep;148(3):783–9. DOI: https://doi.org/10.1016/j.jaci.2021.02.042
Chen H, Kunder R, Zou Y, Staton T, Zhu R, Galanter J, et al. Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation. Pulm Pharmacol Ther. 2022 Aug 1;75:102133. DOI: https://doi.org/10.1016/j.pupt.2022.102133
Luschnig P, Kienzl M, Roula D, Pilic J, Atallah R, Heinemann A, et al. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia. Biochem Pharmacol. 2021 Oct;192:114690. DOI: https://doi.org/10.1016/j.bcp.2021.114690
Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2015 Mar;135(3):676-681.e1. DOI: https://doi.org/10.1016/j.jaci.2014.08.020
Mullol J, Laidlaw TM, Bachert C, Mannent LP, Canonica GW, Han JK, et al. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials. Allergy. 2022 Apr;77(4):1231–44. DOI: https://doi.org/10.1111/all.15067
Ravn NH, Ahmadzay ZF, Christensen TA, Larsen HHP, Loft N, Rævdal P, et al. Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: A systematic review and meta-analysis. J Am Acad Dermatol. 2021 Aug;85(2):453–61. DOI: https://doi.org/10.1016/j.jaad.2020.11.037
Thyssen JP, Halling AS, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI. Comorbidities of atopic dermatitis-what does the evidence say? J Allergy Clin Immunol. 2023 May;151(5):1155–62. DOI: https://doi.org/10.1016/j.jaci.2022.12.002
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019 Sep;181(3):459–73. DOI: https://doi.org/10.1111/bjd.17869
Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W. Ocular Co-Morbidities of Atopic Dermatitis. Part I: Associated Ocular Diseases. Am J Clin Dermatol. 2019 Dec;20(6):797–805. DOI: https://doi.org/10.1007/s40257-019-00455-5
Thaçi D, L Simpson E, Deleuran M, Kataoka Y, Chen Z, Gadkari A, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019 May;94(2):266–75. DOI: https://doi.org/10.1016/j.jdermsci.2019.02.002
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437–49. DOI: https://doi.org/10.1111/bjd.19574
Bakker DS, Ariens LFM, van Luijk C, van der Schaft J, Thijs JL, Schuttelaar MLA, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019 May;180(5):1248–9. DOI: https://doi.org/10.1111/bjd.17538
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021 Sep 1;157(9):1047–55. DOI: https://doi.org/10.1001/jamadermatol.2021.3023
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med. 2021 Mar 25;384(12):1101–12. DOI: https://doi.org/10.1056/NEJMoa2019380
Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol JEADV. 2021 Feb;35(2):476–85. DOI: https://doi.org/10.1111/jdv.16948
Utine CA, Li G, Asbell P, Pflugfelder S, Akpek E. Ocular surface disease associated with dupilumab treatment for atopic diseases. Ocul Surf. 2021 Jan;19:151–6. DOI: https://doi.org/10.1016/j.jtos.2020.05.008
Lortholary O, Fernandez-Ruiz M, Baddley JW, Manuel O, Mariette X, Winthrop KL. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Ann Rheum Dis. 2020 Dec;79(12):1532–43. DOI: https://doi.org/10.1136/annrheumdis-2020-217092
Leung DYM. Why is eczema herpeticum unexpectedly rare? Antiviral Res. 2013 May;98(2):153–7. DOI: https://doi.org/10.1016/j.antiviral.2013.02.010
Traidl S, Roesner L, Zeitvogel J, Werfel T. Eczema herpeticum in atopic dermatitis. Allergy. 2021 Oct;76(10):3017–27. DOI: https://doi.org/10.1111/all.14853
Eichenfield LF, Bieber T, Beck LA, Simpson EL, Thaçi D, de Bruin-Weller M, et al. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. Am J Clin Dermatol. 2019 Jun;20(3):443–56. DOI: https://doi.org/10.1007/s40257-019-00445-7
Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018 Jan;78(1):62-69.e1. DOI: https://doi.org/10.1016/j.jaad.2017.09.052
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2020 Jul 25;396(10246):255–66. DOI: https://doi.org/10.1016/S0140-6736(20)30732-7
Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, et al. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693–707. DOI: https://doi.org/10.1007/s40257-021-00618-3
Narla S, Silverberg JI. Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2018 Jan;120(1):66-72.e11. DOI: https://doi.org/10.1016/j.anai.2017.10.019
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2017 Jun 10;389(10086):2287–303. DOI: https://doi.org/10.1016/S0140-6736(17)31191-1
Ly K, Smith MP, Thibodeaux Q, Beck K, Bhutani T, Liao W. Dupilumab in patients with chronic hepatitis B on concomitant entecavir. JAAD Case Rep. 2019 Jul;5(7):624–6. DOI: https://doi.org/10.1016/j.jdcr.2019.05.007
Matsutani M, Imai Y, Nakatani-Kusakabe M, Natsuaki M, Yamanishi K, Kanazawa N. Dupilumab in atopic dermatitis patients with chronic hepatitis B. J Cutan Immunol Allergy. 2022;5(2):65–6. DOI: https://doi.org/10.1002/cia2.12209
Imai Y, Kusakabe M, Nagai M, Yasuda K, Yamanishi K. Dupilumab Effects on Innate Lymphoid Cell and Helper T Cell Populations in Patients with Atopic Dermatitis. JID Innov Skin Sci Mol Popul Health. 2021 Mar;1(1):100003. DOI: https://doi.org/10.1016/j.xjidi.2021.100003
Wang ST, Tseng CW, Hsu CW, Tung CH, Huang KY, Lu MC, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib. Int J Rheum Dis. 2021 Nov;24(11):1362–9. DOI: https://doi.org/10.1111/1756-185X.14217
Zhang Z, Deng W, Wu Q, Sun L. Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. Immunotherapy. 2019 Mar;11(4):321–33. DOI: https://doi.org/10.2217/imt-2018-0113
Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020 Feb;6(1):e001095. DOI: https://doi.org/10.1136/rmdopen-2019-001095
Avallone G, Trunfio M, Giura MT, Siliquini N, Viola R, Orofino G, et al. Dupilumab in HIV-positive patients with atopic dermatitis: a long-term follow-up patient and a literature review. Dermatol Online J. 2021 Aug 15;27(8). DOI: https://doi.org/10.5070/D327854709
Alawadhi A, Karibayeva D, Gottlieb AB. Dupilumab in HIV-positive patients: A case series report of 4 patients. JAAD Case Rep. 2020 Dec;6(12):1356–9. DOI: https://doi.org/10.1016/j.jdcr.2020.09.023
Edmonds N, Zhao P, Flowers RH. The use of dupilumab in patients with HIV. Int J STD AIDS. 2022 Dec;33(14):1165–73. DOI: https://doi.org/10.1177/09564624221129406
Yasui K. Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-α reagents. Pediatr Rheumatol Online J. 2014;12:45. DOI: https://doi.org/10.1186/1546-0096-12-45
Godfrey MS, Friedman LN. Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor-α and Beyond. Clin Chest Med. 2019 Dec 1;40(4):721–39. DOI: https://doi.org/10.1016/j.ccm.2019.07.003
Sanofi-aventis Canada Inc. Dupixent (Dupilumab) injection. Product monograph. 2022. Available from: https://pdf.hres.ca/dpd_pm/00065186.PDFAccessed: 16 June 2022.
Rook GAW. Th2 cytokines in susceptibility to tuberculosis. Curr Mol Med. 2007 May;7(3):327–37. DOI: https://doi.org/10.2174/156652407780598557
AbbVie Corporation. Rinvoq (Upadacitinib) tablets. Product monograph. 2022. Available from: https://pdf.hres.ca/dpd_pm/00066875.PDFAccessed 16 June 2022.
Pfizer Labs. Cibinqo (Abrocitinib) Tablets. Prescribing information. New York, NY: Pfizer Labs; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213871s000lbl.pdfAccessed 17 June 2022.
Lilly. Baricitnib (Olumiant) tablets. Product monograph. 2022. Available from: https://pi.lilly.com/ca/olumiant-ca-pm.pdf.
Coltro G, Vannucchi AM. The safety of JAK kinase inhibitors for the treatment of myelofibrosis. Expert Opin Drug Saf. 2021 Feb 1;20(2):139–54. DOI: https://doi.org/10.1080/14740338.2021.1865912
Lu Z, Zeng N, Cheng Y, Chen Y, Li Y, Lu Q, et al. Atopic dermatitis and risk of autoimmune diseases: a systematic review and meta-analysis. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol. 2021 Sep 25;17(1):96. DOI: https://doi.org/10.1186/s13223-021-00597-4
Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. DOI: https://doi.org/10.1136/rmdopen-2022-002735
Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3–18. DOI: https://doi.org/10.1136/ard-2022-223356corr1
Eli Lilly and Company. A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis [Internet]. clinicaltrials.gov; 2023 Jul [cited 2023 Jul 24]. Report No.: NCT04086745. Available from: https://clinicaltrials.gov/study/NCT04086745
Nathan J, Hughes C, Patel S, Mathew L, Smith C, Pink A, et al. Ab0573 Dupilumab-Induced Enthesitis/Arthritis in Patients with Atopic Dermatitis: A Retrospective Observational Study. Ann Rheum Dis. 2021 Jun 1;80(Suppl 1):1323–4. DOI: https://doi.org/10.1136/annrheumdis-2021-eular.1363
Willsmore ZN, Woolf RT, Hughes C, Menon B, Kirkham B, Smith CH, et al. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol. 2019 Nov;181(5):1068–70. DOI: https://doi.org/10.1111/bjd.18031
de Wijs LEM, van der Waa JD, de Jong PHP, Hijnen DJ. Acute arthritis and arthralgia as an adverse drug reaction to dupilumab. Clin Exp Dermatol. 2020 Mar;45(2):262–3. DOI: https://doi.org/10.1111/ced.14050
Komaki R, Miyagaki T, Nakajima K, Mitsuishi S, Kishi A, Miyano K, et al. Arthritis and enthesitis during dupilumab therapy completely remitted by celecoxib. J Dermatol. 2021 Jun;48(6):e279–80. DOI: https://doi.org/10.1111/1346-8138.15872
Ishibashi M, Honda T, Tabuchi Y, Kabashima K. Polyenthesitis during treatment with dupilumab for atopic dermatitis. J Eur Acad Dermatol Venereol JEADV. 2020 Jul;34(7):e319–21. DOI: https://doi.org/10.1111/jdv.16239
Chrétien B, Dolladille C, Alexandre J, Fedrizzi S, Lelong-Boulouard V, Lambert JC, et al. Dupilumab-associated arthralgia: an observational retrospective study in VigiBase®. Br J Dermatol. 2021 Aug;185(2):464–5. DOI: https://doi.org/10.1111/bjd.20138
Hughes CD, Nathan J, Mathew L, Pink AE, Woolf RT, Smith C, et al. Characterisation of a musculoskeletal syndrome of enthesitis and arthritis in patients with Atopic Dermatitis treated with Dupilumab, an IL-4/13 inhibitor. Arthritis Rheumatol Hoboken NJ. 2023 May 10; DOI: https://doi.org/10.1002/art.42558
Bostan E, Gülseren D, Özsoy Z, Ergen FB. Reactivation of inflammatory monoarthritis during dupilumab treatment used for prurigo nodularis. Arch Rheumatol. 2022;37(1):148–9. DOI: https://doi.org/10.46497/ArchRheumatol.2022.8780
Bridgewood C, Wittmann M, Macleod T, Watad A, Newton D, Bhan K, et al. T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases. J Invest Dermatol. 2022 Oct;142(10):2660–7. DOI: https://doi.org/10.1016/j.jid.2022.03.013
Bridgewood C, Sharif K, Freeston J, Saleem B, Russell T, Watad A, et al. Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy. Rheumatol Oxf Engl. 2021 May 14;60(5):2461–6. DOI: https://doi.org/10.1093/rheumatology/keaa568
Shimodaira Y, Takahashi S, Iijima K. Anti-IL-4Ralpha monoclonal antibody dupilumab mimics ulcerative colitis: a case report. BMC Gastroenterol. 2021 May 8;21(1):207. DOI: https://doi.org/10.1186/s12876-021-01803-8
Pagan AD, Ghalili S, Cices A, Facheris P, Tan K, Ungar B, et al. Atopic dermatitis induced during anti-TNF-α therapy for inflammatory bowel disease: Potential for Th2 inhibition with dupilumab. J Allergy Clin Immunol Pract. 2023 Jul;11(7):2235-2238.e1. DOI: https://doi.org/10.1016/j.jaip.2023.03.054
Spencer EA, Dolinger MT, Dubinsky MC. A Single-Center Experience with Dupilumab for Atopic or Psoriasiform Dermatitis in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2023 Apr;68(4):1121–4. DOI: https://doi.org/10.1007/s10620-022-07684-5
Giuffrida P, Caprioli F, Facciotti F, Di Sabatino A. The role of interleukin-13 in chronic inflammatory intestinal disorders. Autoimmun Rev. 2019 May;18(5):549–55. DOI: https://doi.org/10.1016/j.autrev.2019.03.012
Danese S, Rudziński J, Brandt W, Dupas JL, Peyrin-Biroulet L, Bouhnik Y, et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut. 2015 Feb;64(2):243–9. DOI: https://doi.org/10.1136/gutjnl-2014-308004
Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D’Haens G, et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease. Gastroenterology. 2020 Jun;158(8):2123-2138.e8. DOI: https://doi.org/10.1053/j.gastro.2020.01.047
Ghosh S, Sanchez Gonzalez Y, Zhou W, Clark R, Xie W, Louis E, et al. Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. J Crohns Colitis. 2021 Dec 18;15(12):2022–30. DOI: https://doi.org/10.1093/ecco-jcc/jjab099
D’Haens G, Panés J, Louis E, Lacerda A, Zhou Q, Liu J, et al. Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn’s Disease in the CELEST Extension Study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2022 Oct;20(10):2337-2346.e3. DOI: https://doi.org/10.1016/j.cgh.2021.12.030
Grieco T, Caviglia M, Cusano G, Sernicola A, Chello C, Del Duca E, et al. Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib. Medicina (Mex). 2023 Mar;59(3):542. DOI: https://doi.org/10.3390/medicina59030542
Friedberg S, Choi D, Hunold T, Choi NK, Garcia NM, Picker EA, et al. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn’s Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2023 Jul;21(7):1913-1923.e2. DOI: https://doi.org/10.1016/j.cgh.2023.03.001
Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis. Gut. 2023 Feb;72(2):264–74. DOI: https://doi.org/10.1136/gutjnl-2022-328052
Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology. 2020 May;158(6):1554-1573.e12. DOI: https://doi.org/10.1053/j.gastro.2020.01.001
Loftus EV, Panés J, Lacerda AP, Peyrin-Biroulet L, D’Haens G, Panaccione R, et al. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2023 May 25;388(21):1966–80. DOI: https://doi.org/10.1056/NEJMoa2212728
Chugh R, Braga-Neto MB, Fredrick TW, Ramos GP, Terdiman J, El-Nachef N, et al. Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn’s Disease. J Crohns Colitis. 2023 Apr 19;17(4):504–12. DOI: https://doi.org/10.1093/ecco-jcc/jjac157
Tsai YC, Tsai TF. Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes. Int J Mol Sci. 2022 May 15;23(10):5518. DOI: https://doi.org/10.3390/ijms23105518
Patruno C, Napolitano M, Ferrillo M, Fabbrocini G. Dupilumab and alopecia: A Janus effect. Dermatol Ther. 2019 Sep;32(5):e13023. DOI: https://doi.org/10.1111/dth.13023
Beaziz J, Bouaziz JD, Jachiet M, Fite C, Lons-Danic D. Dupilumab-induced psoriasis and alopecia areata: Case report and review of the literature. Ann Dermatol Venereol. 2021 Sep;148(3):198–201. DOI: https://doi.org/10.1016/j.annder.2021.02.003
Maiolini VM, Sousa NA, Marsillac PF de, Bressan AL. Alopecia areata-like and psoriasis after dupilumab use for atopic dermatitis. An Bras Dermatol. 2021;96(5):634–6. DOI: https://doi.org/10.1016/j.abd.2021.03.005
Chung J, Slaught CL, Simpson EL. Alopecia areata in 2 patients treated with dupilumab: New onset and worsening. JAAD Case Rep. 2019 Aug;5(8):643–5. DOI: https://doi.org/10.1016/j.jdcr.2019.03.019
Kulkarni M, Rohan CA, Morris D, Travers JB. Resolution of dupilumab-associated alopecia areata with dosage modification. JAAD Case Rep. 2022 Apr;22:85–8. DOI: https://doi.org/10.1016/j.jdcr.2022.01.034
Yazdanyar S, Jemec GBE. Alopecia Areata After Treatment with Dupilumab. Dermat Contact Atopic Occup Drug. 2019;30(2):175–6. DOI: https://doi.org/10.1097/DER.0000000000000458
Carnicle JM, Hendricks AJ, Shi VY. Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis. Dermat Contact Atopic Occup Drug. 2021 Oct 1;32(1S):e80–2. DOI: https://doi.org/10.1097/DER.0000000000000512
Yamane S, Nakagawa Y, Inui S, Fujimoto M. Development of alopecia areata-like reactions in a patient treated with dupilumab. Allergol Int Off J Jpn Soc Allergol. 2022 Jul;71(3):420–2. DOI: https://doi.org/10.1016/j.alit.2022.02.006
Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. JAAD Case Rep. 2018 Mar;4(2):143–4. DOI: https://doi.org/10.1016/j.jdcr.2017.11.020
Sachdeva M, Witol A, Mufti A, Maliyar K, Yeung J. Alopecia Areata Related Paradoxical Reactions in Patients on Dupilumab Therapy: A Systematic Review. J Cutan Med Surg. 2021;25(4):451–2. DOI: https://doi.org/10.1177/1203475421995186
Jin P, Wei L, Zhang Q, Gao T, Bai J, Dong L, et al. Dupilumab for alopecia areata treatment: A double-edged sword? J Cosmet Dermatol. 2022 Nov;21(11):5546–8. DOI: https://doi.org/10.1111/jocd.15136
Bur D, Kim K, Rogge M. Dupilumab Induced Hair Regrowth in Alopecia Totalis. J Drugs Dermatol JDD. 2023 Apr 1;22(4):410–2. DOI: https://doi.org/10.36849/JDD.6254
Gruenstein D, Malik K, Levitt J. Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab. JAAD Case Rep. 2020 Dec;6(12):1286–7. DOI: https://doi.org/10.1016/j.jdcr.2020.10.010
McKenzie PL, Castelo-Soccio L. Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis. J Am Acad Dermatol. 2021 Jun;84(6):1691–4. DOI: https://doi.org/10.1016/j.jaad.2021.01.046
Alotaibi L, Alfawzan A, Alharthi R, Al Sheikh A. Improvement of atopic dermatitis and alopecia universalis with dupilumab. Dermatol Rep. 2022 Jun 16;14(2):9359. DOI: https://doi.org/10.4081/dr.2022.9359
Cho SK, Craiglow BG. Dupilumab for the treatment of alopecia areata in children with atopic dermatitis. JAAD Case Rep. 2021 Oct;16:82–5. DOI: https://doi.org/10.1016/j.jdcr.2021.07.015
Ludriksone L, Elsner P, Schliemann S. Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2019 Dec;17(12):1278–80. DOI: https://doi.org/10.1111/ddg.13990
Renert-Yuval Y, Pavel AB, Del Duca E, Facheris P, Pagan AD, Bose S, et al. Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. Allergy. 2023 Apr;78(4):1047–59. DOI: https://doi.org/10.1111/all.15561
Magdaleno-Tapial J, Valenzuela-Oñate C, García-Legaz-Martínez M, Martínez-Domenech Á, Pérez-Ferriols A. Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature. Australas J Dermatol. 2020;61(2):e223–5. DOI: https://doi.org/10.1111/ajd.13208
Marks DH, Mesinkovska N, Senna MM. Cause or cure? Review of dupilumab and alopecia areata. J Am Acad Dermatol. 2023 Mar;88(3):651–3. DOI: https://doi.org/10.1016/j.jaad.2019.06.010
Guttman-Yassky E, Renert-Yuval Y, Bares J, Chima M, Hawkes JE, Gilleaudeau P, et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients. Allergy. 2022 Mar;77(3):897–906. DOI: https://doi.org/10.1111/all.15071
https://www.gazzettaufficiale.it/eli/gu/2023/07/07/157/sg/pdf.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5;386(18):1687–99. DOI: https://doi.org/10.1056/NEJMoa2110343
MASHIKO R, OKA D, AOYAMA Y. Effect of JAK Inhibitor on Atopic Dermatitis Patients Associated with Alopecia Areata. Nishinihon J Dermatol. 2023 Feb 1;85:34–7. DOI: https://doi.org/10.2336/nishinihonhifu.85.34
Uchida H, Kamata M, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, et al. Baricitinib improved alopecia areata concomitant with atopic dermatitis: A case report. J Dermatol. 2021;48(9):e472–3. DOI: https://doi.org/10.1111/1346-8138.16024
https://clinicaltrials.gov/study/NCT02684097.
Chiricozzi A, Balato A, Fabbrocini G, Di Nardo L, Babino G, Rossi M, et al. Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: a multicenter retrospective study. J Am Acad Dermatol. 2023 May 9;S0190-9622(23)00765-X. DOI: https://doi.org/10.1016/j.jaad.2023.05.001
Cantelli M, Martora F, Patruno C, Nappa P, Fabbrocini G, Napolitano M. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report. Dermatol Ther. 2022 Apr;35(4):e15346. DOI: https://doi.org/10.1111/dth.15346
Yu D, Ren Y. Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review. Acta Derm Venereol. 2023 Apr 4;103:adv5578. DOI: https://doi.org/10.2340/actadv.v103.5578
Bourkas AN, Sibbald C. Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report. SAGE Open Med Case Rep. 2022;10:2050313X221138452. DOI: https://doi.org/10.1177/2050313X221138452
Bennett M, Moussa A, Sinclair R. Successful treatment of chronic severe alopecia areata with abrocitinib. Australas J Dermatol. 2022 May;63(2):274–6. DOI: https://doi.org/10.1111/ajd.13836
Zhao J, Liu L. A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib. JAAD Case Rep. 2022 Apr;22:99–100. DOI: https://doi.org/10.1016/j.jdcr.2022.02.027
Huang J, Liu O. Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib. J Cosmet Dermatol. 2023 Jun 29; DOI: https://doi.org/10.1111/jocd.15896
Picone V, Napolitano M, Torta G, Fabbrocini G, Patruno C. Vitiligo during dupilumab therapy. JAAD Case Rep. 2023 Jun;36:51–3. DOI: https://doi.org/10.1016/j.jdcr.2023.03.025
Ren H, Akabane AL, Kelleher K, Halverstam C, Hicks M, Schachter JR, et al. Vitiligo induced by dupilumab treatment: A case series. J Eur Acad Dermatol Venereol [Internet]. 2023 [cited 2023 Jul 18]; Available from: https://scholars.mssm.edu/en/publications/vitiligo-induced-by-dupilumab-treatment-a-case-series DOI: https://doi.org/10.1111/jdv.19132
Takeoka S, Kamata M, Yokoi I, Takehara A, Tada Y. Rapid Enlargement of Vitiligo Vulgaris after Initiation of Dupilumab for Atopic Dermatitis: A Case Report. Acta Derm Venereol. 2021 Oct 28;101(10):adv00581. DOI: https://doi.org/10.2340/actadv.v101.545
Napolitano M, Fabbrocini G, Patruno C. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study. J Dermatol. 2023 Jul;50(7):880–7. DOI: https://doi.org/10.1111/1346-8138.16764
Pan T, Mu Y, Shi X, Chen L. Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report. J Dermatol Treat. 2023 Dec;34(1):2200873. DOI: https://doi.org/10.1080/09546634.2023.2200873
Dong J, Huang X, Ma LP, Qi F, Wang SN, Zhang ZQ, et al. Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro. Dose-Response Publ Int Hormesis Soc. 2022;20(2):15593258221105370. DOI: https://doi.org/10.1177/15593258221105370
Mumford BP, Gibson A, Chong AH. Repigmentation of vitiligo with oral baricitinib. Australas J Dermatol. 2020 Nov;61(4):374–6. DOI: https://doi.org/10.1111/ajd.13348
Li X, Sun Y, Du J, Wang F, Ding X. Excellent Repigmentation of Generalized Vitiligo with Oral Baricitinib Combined with NB-UVB Phototherapy. Clin Cosmet Investig Dermatol. 2023;16:635–8. DOI: https://doi.org/10.2147/CCID.S396430
Su Z, Zeng YP. Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review. Dermatology. 2023 Apr 26;1–1.
Gori N, Caldarola G, Pirro F, De Simone C, Peris K. A case of guttate psoriasis during treatment with dupilumab. Dermatol Ther. 2019 Sep;32(5):e12998. DOI: https://doi.org/10.1111/dth.12998
Napolitano M, Scalvenzi M, Fabbrocini G, Cinelli E, Patruno C. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series. Dermatol Ther. 2019 Nov;32(6):e13142. DOI: https://doi.org/10.1111/dth.13142
Ferrucci S, Tavecchio S, Berti E, Angileri L. Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab. Clin Exp Dermatol. 2020 Jul;45(5):625–6. DOI: https://doi.org/10.1111/ced.14207
D’Ambra I, Babino G, Fulgione E, Calabrese G, Ronchi A, Alfano R, et al. Psoriasis onset under dupilumab treatment in two patients affected by Atopic Dermatitis and one patient affected by Alopecia Areata: clinical and dermoscopic patterns. Dermatol Ther. 2020 Sep 8;33. DOI: https://doi.org/10.1111/dth.14169
Russo F, Provvidenziale L, Bruzziches F, Fiorani D, Santi F, Lamberti A, et al. Psoriasis-like Eruption triggered by Dupilumab Therapy. Dermat Contact Atopic Occup Drug. 2021 Dec 1;32(6):e147–8. DOI: https://doi.org/10.1097/DER.0000000000000740
Casale F, Nguyen C, Dobry A, Smith J, Mesinkovska NA. Dupilumab-associated psoriasis and psoriasiform dermatitis in patients with atopic dermatitis. Australas J Dermatol. 2022 Aug;63(3):394–7. DOI: https://doi.org/10.1111/ajd.13846
Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: A systematic review. J Am Acad Dermatol. 2022 Mar;86(3):708–9. DOI: https://doi.org/10.1016/j.jaad.2021.05.013
Flanagan KE, Pupo Wiss IM, Pathoulas JT, Walker CJ, Senna MM. Dupilumab-induced psoriasis in a patient with atopic dermatitis and alopecia totalis: A case report and literature review. Dermatol Ther. 2022 Feb;35(2):e15255. DOI: https://doi.org/10.1111/dth.15255
Parker JJ, Sugarman JL, Silverberg NB, Gonzalez ME, Ramien ML, Teng JMC, et al. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children. Pediatr Dermatol. 2021;38(6):1500–5. DOI: https://doi.org/10.1111/pde.14820
Colonna C, Bortoluzzi P, Cavalli R. Dupilumab treatment for severe atopic dermatitis in children and SARS-CoV-2 infection: A combination of triggers for psoriasis. J Eur Acad Dermatol Venereol JEADV. 2023 May;37(5):e568–9. DOI: https://doi.org/10.1111/jdv.18864
Varma A, Levitt J. Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis. JAAD Case Rep. 2020 Feb 19;6(3):217–8. DOI: https://doi.org/10.1016/j.jdcr.2020.01.012
Al Hawsawi K, AlDoboke AW, Alsulami SA, Alamri GE, Alsufi RF. Dupilumab-Induced Scalp Psoriasis in a Patient With Prurigo Nodularis: A Case Report. Cureus [Internet]. 2023 Apr 22 [cited 2023 Jul 19]; Available from: https://www.cureus.com/articles/148198-dupilumab-induced-scalp-psoriasis-in-a-patient-with-prurigo-nodularis-a-case-report DOI: https://doi.org/10.7759/cureus.37992
Tracey EH, Elston C, Feasel P, Piliang M, Michael M, Vij A. Erythrodermic presentation of psoriasis in a patient treated with dupilumab. JAAD Case Rep. 2018 Aug;4(7):708–10. DOI: https://doi.org/10.1016/j.jdcr.2018.05.014
Jia X, Li C, Wu J, Liu Q. Pustular Psoriasis Appearing Induced by Dupilumab Therapy in a Patient With Atopic Dermatitis. J Drugs Dermatol JDD. 2022 Mar 1;21:311–2.
Stout M, Guitart J, Tan T, Silverberg JI. Psoriasis-like Dermatitis Developing in a Patient with Atopic Dermatitis Treated with Dupilumab. Dermat Contact Atopic Occup Drug. 2019;30(6):376–8. DOI: https://doi.org/10.1097/DER.0000000000000509
Fowler E, Silverberg JI, Fox JD, Yosipovitch G. Psoriasiform Dermatitis After Initiation of Treatment with Dupilumab for Atopic Dermatitis. Dermat Contact Atopic Occup Drug. 2019;30(3):234–6. DOI: https://doi.org/10.1097/DER.0000000000000481
Napolitano M, Caiazzo G, Fabbrocini G, Balato A, Di Caprio R, Scala E, et al. Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment. Br J Dermatol. 2021 Feb;184(2):341–3. DOI: https://doi.org/10.1111/bjd.19459
Mirza FN, Wang A, Ramachandran SM, Damsky W, Cohen JM. Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report. Br J Dermatol. 2021 Aug;185(2):432–4. DOI: https://doi.org/10.1111/bjd.20064
Mease PJ, Lertratanakul A, Papp KA, van den Bosch FE, Tsuji S, Dokoupilova E, et al. Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. Rheumatol Ther. 2021 Jun;8(2):903–19. DOI: https://doi.org/10.1007/s40744-021-00305-z
Gargiulo L, Ibba L, Pavia G, Avagliano J, Cortese A, Costanzo A, et al. Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series. J Dermatol Treat. 2023 Dec;34(1):2183729. DOI: https://doi.org/10.1080/09546634.2023.2183729
Patruno C, Fabbrocini G, De Lucia M, Picone V, Genco L, Napolitano M. Psoriasiform dermatitis induced by dupilumab successfully treated with upadacitinib. Dermatol Ther. 2022 Nov;35(11):e15788. DOI: https://doi.org/10.1111/dth.15788
Ferrucci SM, Buffon S, Marzano AV, Maronese CA. Phenotypic switch from atopic dermatitis to psoriasis during treatment with upadacitinib. Clin Exp Dermatol. 2022 May;47(5):986–7. DOI: https://doi.org/10.1111/ced.15104
Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016 Jun;174(6):1266–76. DOI: https://doi.org/10.1111/bjd.14403
Tada Y, Ono N, Koarada S. Immediate Effect of Baricitinib on Arthritis and Biological Disease-Modifying Antirheumatic Drug-Induced Psoriasis-Like Skin Lesions in Two Patients with Rheumatoid Arthritis. Case Rep Rheumatol. 2021;2021:8876847. DOI: https://doi.org/10.1155/2021/8876847
Mansfield KE, Schmidt SAJ, Darvalics B, Mulick A, Abuabara K, Wong AYS, et al. Association Between Atopic Eczema and Cancer in England and Denmark. JAMA Dermatol. 2020 Oct 1;156(10):1086–97. DOI: https://doi.org/10.1001/jamadermatol.2020.1948
Ishida M, Hodohara K, Yoshii M, Okuno H, Horinouchi A, Shirakawa A, et al. Primary cutaneous anaplastic large cell lymphoma occurring in an atopic dermatitis patient: a case report with review of the literature with emphasis on their association. Int J Clin Exp Pathol. 2014;7(4):1735–41.
Sechi A, Guglielmo A, Patrizi A, Bertuzzi C, Neri I, Pileri A. Atopic dermatitis and mycosis fungoides in a child: an overlooked association. Ital J Dermatol Venereol. 2021 Oct;156(5):625–6. DOI: https://doi.org/10.23736/S2784-8671.20.06856-X
Owji S, Ungar B, Dubin DP, Poplausky D, Young JN, Ghalili S, et al. No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol Pract. 2023 May;11(5):1548–51. DOI: https://doi.org/10.1016/j.jaip.2022.12.018
Fowler E, Rosen J, Lev-Tov H, Yosipovitch G. Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis. Acta Derm Venereol. 2019 Sep 1;99(10):899–900. DOI: https://doi.org/10.2340/00015555-3201
Siliquini N, Giura MT, Viola R, Ribero S, Panzone M, Dapavo P, et al. Atopic dermatitis, dupilumab and cancers: a case series. J Eur Acad Dermatol Venereol JEADV. 2021 Oct;35(10):e651–2. DOI: https://doi.org/10.1111/jdv.17264
Tanczosova M, Hugo J, Gkalpakiotis S. Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer. J Clin Med. 2023 Feb 2;12(3):1191. DOI: https://doi.org/10.3390/jcm12031191
Belmesk L, Muntyanu A, Cantin E, AlHalees Z, Jack CS, Le M, et al. Prominent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis. J Cutan Med Surg. 2022;26(1):33–49. DOI: https://doi.org/10.1177/12034754211027858
Elston DM. Dupilumab and cutaneous T-cell lymphoma. J Am Acad Dermatol. 2020 Jul;83(1):33–4. DOI: https://doi.org/10.1016/j.jaad.2020.03.051
Park A, Wong L, Lang A, Kraus C, Anderson N, Elsensohn A. Cutaneous T-cell lymphoma following dupilumab use: a systematic review. Int J Dermatol. 2023 Jul;62(7):862–76. DOI: https://doi.org/10.1111/ijd.16388
Poyner EFM, Bacon CM, Osborne W, Frew JA, Weatherhead SC. Dupilumab unmasking cutaneous T-cell lymphoma: report of a fatal case. Clin Exp Dermatol. 2022 May;47(5):974–6. DOI: https://doi.org/10.1111/ced.15079
Kołkowski K, Trzeciak M, Sokołowska-Wojdyło M. Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas. Int J Mol Sci. 2021 Dec 13;22(24):13388. DOI: https://doi.org/10.3390/ijms222413388
Russomanno K, Carver DeKlotz CM. Acceleration of cutaneous T-cell lymphoma following dupilumab administration. JAAD Case Rep. 2021 Feb;8:83–5. DOI: https://doi.org/10.1016/j.jdcr.2020.12.010
Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, et al. Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. J Am Acad Dermatol. 2020 Jul;83(1):197–9.
Hollins LC, Wirth P, Fulchiero GJ, Foulke GT. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. Cutis. 2020 Aug;106(2):E8–11. DOI: https://doi.org/10.12788/cutis.0074
Du-Thanh A, Gustave V, Dereure O. Lethal anaplastic large-cell lymphoma occurring in a patient treated with dupilumab. JAAD Case Rep. 2021 Dec;18:4–7. DOI: https://doi.org/10.1016/j.jdcr.2021.09.020
Saad S, Ram-Wolff C, De Masson A, Jachiet M, Battistella M, Vignon-Pennamen MD, et al. CD30-positive anaplastic large-cell lymphoma associated with mycosis fungoides after treatment with dupilumab. Eur J Dermatol EJD. 2022 Jul 1;32(4):536–7. DOI: https://doi.org/10.1684/ejd.2022.4279
Ahatov R, Good AJ, Joo M, Tipton S, Goodwin B, Kelly B. A rare case of aggressive cytotoxic T-cell lymphoma in a patient on dupilumab. JAAD Case Rep. 2022 Jun;24:112–4. DOI: https://doi.org/10.1016/j.jdcr.2022.04.023
Choo ZY, Akinyemi AA, Cibull T, Mehlis S, Waldinger JB. Angioimmunoblastic T-cell lymphoma unmasked by treatment with dupilumab. JAAD Case Rep. 2023 Mar;33:87–90. DOI: https://doi.org/10.1016/j.jdcr.2023.01.008
Nakazaki K, Yoshida M, Masamoto Y, Shinozaki-Ushiku A, Ikemura M, Hisamoto T, et al. Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. Int J Hematol. 2022 Sep;116(3):446–52. DOI: https://doi.org/10.1007/s12185-022-03330-y
Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022 Oct;87(4):815–24. DOI: https://doi.org/10.1016/j.jaad.2022.07.019
Samuel C, Cornman H, Kambala A, Kwatra SG. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring. Dermatol Ther. 2023 Mar;13(3):729–49. DOI: https://doi.org/10.1007/s13555-023-00892-5
https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki.
Ytterberg SR, Bhatt DL, Connell CA. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply. N Engl J Med. 2022 May 5;386(18):1768. DOI: https://doi.org/10.1056/NEJMc2202778
Balakirski G, Novak N. Atopic dermatitis and pregnancy. J Allergy Clin Immunol. 2022 Apr;149(4):1185–94. DOI: https://doi.org/10.1016/j.jaci.2022.01.010
Khamisy-Farah R, Damiani G, Kong JD, Wu JH, Bragazzi NL. Safety profile of Dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBaseTM). Eur Rev Med Pharmacol Sci. 2021 Sep;25(17):5448–51.
Escolà H, Figueras-Nart I, Bonfill-Orti M, Coll Puigserver N, Martin-Santiago A, Rodríguez Serna M, et al. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: Clinical experience in 13 patients. J Eur Acad Dermatol Venereol JEADV. 2023 May 5; DOI: https://doi.org/10.1111/jdv.19165
Gracia-Darder I, Pons De Ves J, Reyero Cortina M, Martín-Santiago A. Patient with atopic dermatitis, hyper IgE syndrome and ulcerative colitis, treated successfully with dupilumab during pregnancy. Dermatol Ther. 2022 Feb;35(2):e15237. DOI: https://doi.org/10.1111/dth.15237
L Ramos C, Namazy J. Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation. Immunol Allergy Clin North Am. 2023 Feb;43(1):187–97. DOI: https://doi.org/10.1016/j.iac.2022.07.001
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2022 Sep 17;400(10356):908–19. DOI: https://doi.org/10.1016/S0140-6736(22)01539-2
Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020 Nov;83(5):1282–93. DOI: https://doi.org/10.1016/j.jaad.2020.06.054
Stingeni L, Bianchi L, Antonelli E, Caroppo ES, Ferrucci SM, Ortoncelli M, et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. J Eur Acad Dermatol Venereol JEADV. 2022 Aug;36(8):1292–9. DOI: https://doi.org/10.1111/jdv.18141
Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HCH, et al. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatol. 2023 Jun 1;159(6):596–605. DOI: https://doi.org/10.1001/jamadermatol.2023.0627
Silverberg JI, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Costanzo A, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. J Allergy Clin Immunol. 2022 Mar;149(3):977-987.e14. DOI: https://doi.org/10.1016/j.jaci.2021.07.036
Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HCH, Katoh N, et al. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022 Apr 1;158(4):404–13. DOI: https://doi.org/10.1001/jamadermatol.2022.0029
Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, et al. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatol. 2023 May 1;159(5):526–35. DOI: https://doi.org/10.1001/jamadermatol.2023.0391
De Greef A, Ghislain PD, de Montjoye L, Baeck M. Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults. Adv Ther. 2023 May 1;40(5):2509–14. DOI: https://doi.org/10.1007/s12325-023-02490-5
Cork MJ, McMichael A, Teng J, Valdez H, Rojo R, Chan G, et al. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. J Eur Acad Dermatol Venereol JEADV. 2022 Mar;36(3):422–33. DOI: https://doi.org/10.1111/jdv.17792
Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, et al. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial. JAMA Dermatol. 2021 Oct 1;157(10):1165–73. DOI: https://doi.org/10.1001/jamadermatol.2021.2830
Torrelo A, Rewerska B, Galimberti M, Paller A, Yang CY, Prakash A, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023 Jul 7;189(1):23–32. DOI: https://doi.org/10.1093/bjd/ljad096
Tanei R, Hasegawa Y. Atopic dermatitis in older adults: A viewpoint from geriatric dermatology. Geriatr Gerontol Int. 2016;16(S1):75–86. DOI: https://doi.org/10.1111/ggi.12771
Chello C, Carnicelli G, Sernicola A, Gagliostro N, Paolino G, Di Fraia M, et al. Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature. Int J Dermatol. 2020 Jun;59(6):716–21. DOI: https://doi.org/10.1111/ijd.14891
Lam M, Zhu JW, Maqbool T, Adam G, Tadrous M, Rochon P, et al. Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic Dermatitis: A Systematic Review. JAMA Dermatol. 2020 Nov 1;156(11):1240–5. DOI: https://doi.org/10.1001/jamadermatol.2020.2940
Napolitano M, Fabbrocini G, Scalvenzi M, Blasio C, Stingeni L, Patruno C. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study. Clin Exp Dermatol. 2020 Oct;45(7):888–90. DOI: https://doi.org/10.1111/ced.14260
Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol JEADV. 2021 Apr;35(4):958–64. DOI: https://doi.org/10.1111/jdv.17094
Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L, et al. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study. Am J Clin Dermatol. 2021 Jul;22(4):581–6. DOI: https://doi.org/10.1007/s40257-021-00597-5
LEO Pharma announces FDA approval of AdbryTM (tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis.
Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet Lond Engl. 2021 Jun 5;397(10290):2151–68. DOI: https://doi.org/10.1016/S0140-6736(21)00588-2
Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis. JAMA Dermatol. 2020 Dec;156(12):1–11. DOI: https://doi.org/10.1001/jamadermatol.2020.3260
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
